Prosecution Insights
Last updated: August 16, 2026

Elanco Tiergesundheit AG

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
1
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (20%)
4
Medium (80%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (60%)
Double-patenting + other1 (20%)
Multi-statute (no §101)1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
80% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
20% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HERNANDEZ, JACKSON J 1 50.9% +28.8%
LEE, CHIHYI NMN 1 32.9% +58.5%
SONG, JIANFENG 1 56.2% +33.1%
RAMACHANDRAN, UMAMAHESWARI 1 54.5% +53.8%
STIGELL, THEODORE J 1 78.3% +14.8%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18255134 BICYCLIC DERIVATIVES HERNANDEZ, JACKSON J

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18109410 MONENSIN LEVELS FOR MODERN DAIRY DIET RAMACHANDRAN, UMAMAHESWARI 99d overdue
18253061 N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS LEE, CHIHYI NMN 60d overdue
18043868 CHEWABLE FORMULATIONS SONG, JIANFENG 14d
17795341 WINGED CAPSULE STIGELL, THEODORE J 29d
18255134 BICYCLIC DERIVATIVES HERNANDEZ, JACKSON J

Top Art Units

Art UnitApps
1627 2
1628 1
1613 1
3783 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18255134 BICYCLIC DERIVATIVES HERNANDEZ, JACKSON J 1627 §103§112Other Final Rejection Pending May 31, 2023
18253061 N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS LEE, CHIHYI NMN 1628 §102§103§112DP Final Rejection 60d overdue Pending May 16, 2023
18043868 CHEWABLE FORMULATIONS SONG, JIANFENG 1613 §103 Final Rejection 14d Pending Mar 02, 2023
18109410 MONENSIN LEVELS FOR MODERN DAIRY DIET RAMACHANDRAN, UMAMAHESWARI 1627 §103 Non-Final OA 99d overdue Pending Feb 14, 2023
17795341 WINGED CAPSULE STIGELL, THEODORE J 3783 §103 Final Rejection 29d Pending Jul 26, 2022

Managing Elanco Tiergesundheit AG's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month